Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kiadis Pharma has reported promising Phase II clinical trial results for Reviroc, which is used to eliminate cancer cells. The drug improved overall survival of patients tested.
Subscribe to our email newsletter
The drug eliminates cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
The successful completion of the clinical trial allows Kiadis Pharma to prepare for a Phase III clinical study.
Manja Bouman, CEO, Kiadis Pharma, comments: “Reviroc shares its development platform with two other Kiadis Pharma products: ATIR and Rhitol. The results of this trial therefore mark an important milestone in the development of our entire clinical product pipeline.”
In the non-randomized open label study, 25 patients, each of whom had reached end stage non-Hodgkin’s lymphoma, were treated in multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that the drug does not negatively impact the graft itself.
The Reviroc clinical trial data was evaluated against a historical patient control group from the center for international blood and marrow transplant research (CIBMTR).
The results for Reviroc-treated patients were compared with results from the CIBMTR database for patients who had received an autologous transplant without Reviroc. The outcome of this comparison shows that the Reviroc-treated patient group had an 80% chance of survival at three years post transplantation, while the CIBMTR control group had a 55% chance of survival at three years post transplantation.
Based on these promising data, Kiadis Pharma will prepare for a clinical Phase III study of Reviroc.